author-photo

Graham Jackson

Newcastle University
University of Newcastle
Royal Victoria Infirmary

624

Papers

15659

Citations

Citation Trend

Filter By

Papers (624) Sort By

Journal Conference Others

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Unifying the Definition of High-Risk in Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Multistate Models Demonstrate That Lenalidomide Maintenance Enhances Survival By Prolonging Time in First Remission for Patients Treated in the UK NCRI Myeloma XI Randomised Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Enrolment and Outcomes of Ethnic Minorities with Multiple Myeloma Treated in UK Myeloma Research Alliance (UK-MRA) Clinical Trials over 18 Years

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network.

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation.

2021 Expert Opinion on Drug Safety
Show All
- Source
- Cite
- Save
Citations (0)
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

2021 PLOS Medicine
Show All
- Source
- Cite
- Save
Citations (1)